Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Therapeutic Effects of Berberine Plus Sitagliptin in a Rat Model of Fatty Liver Disease Publisher



Mehrdoost S1 ; Yaghmaei P1 ; Jafary H1 ; Ebrahimhabibi A2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biology, Faculty of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
  2. 2. Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Iran

Source: Iranian Journal of Basic Medical Sciences Published:2021


Abstract

Objective(s): Fatty liver disease (FLD) is a disorder related to accumulation of excess fat within the hepatocytes. In this study, the effects of berberine, a natural compound, and sitagliptin as a DPP-4 inhibitor, were observed in a rat model of FLD. Materials and Methods: Forty male rats were divided into five groups (n=6) including the control group (normal food and water), high-fat group (high-fat diet (HF) for 6 weeks), berberine group (HF with oral administration of berberine at 150 mg/kg for 6 weeks), sitagliptin group (HF with oral administration of sitagliptin at 10 mg/kg for 6 weeks), and berberine/ sitagliptin group (HF diet within combination with oral administration of berberine 75 mg/kg and sitagliptin 5 mg/kg for 6 weeks). Animals were examined for weight gain, serum and hepatic biochemical parameters, tissue histology, expression of glucose transporter type 4 (GLUT4) mRNA, and protein expression of Adiponectin receptor2 (AdipoR2) and extracellular signal-regulated kinase (ERK) and phoERK. Results: The results showed that ALT, AST, lipid profile, insulin, glucose, MDA, and TNF-α were significantly improved in high-fat rats treated with berberine/ sitagliptin compared with HF and sitagliptin, and berberine alone groups. SOD and adiponectin levels in berberine/ sitagliptin group were also significantly increased compared with the other groups. Immunoblot analysis showed that the expression of pho-ERK/ERK was significantly decreased and expression of AdipoR2 significantly increased in the berberine/ sitagliptin group compared with other groups. Conclusion: Co-administration of berberine and sitagliptin is an effective therapeutic regimen for conditions associated with hyperlipidemia. © 2021 Mashhad University of Medical Sciences. All rights reserved.